Dr. Anthony S. Stein
Hematologist Oncologist · Hematologic CancersDr. Anthony S. Stein, MD, is a nationally recognized leader in hematologic oncology and a longtime faculty member at City of Hope, where he specializes in acute leukemias and stem cell transplantation. He earned his medical degree from the University of Cape Town in South Africa and completed his residency in internal medicine at Montefiore Medical Center in Pittsburgh. He then pursued a fellowship in hematology and oncology at City of Hope, joining the faculty in 1988. He currently serves as Associate Director of the Gehr Family Center for Leukemia Research and is a Professor in the Division of Leukemia and Department of Hematology & Hematopoietic Cell Transplantation. With over 35 years of experience, Dr. Stein provides care for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes, and stem cell transplant candidates through in-person and telehealth appointments.
He is widely respected for his leadership in clinical research and trial development. He serves as principal investigator on multiple studies exploring new therapeutic agents for acute leukemias, including novel drugs and advanced conditioning regimens for transplantation. His work includes trials of venetoclax-based combinations and targeted agents in AML, and he participates in innovative studies examining total marrow and lymphoid irradiation with post-transplant cyclophosphamide. He also contributes to efforts involving cellular immunotherapies, such as NK- or CAR-T cell–based treatments for leukemia. His research activities extend across both early phase and practice-changing trials, helping bring novel treatments from the lab to clinical care.
Dr. Stein has earned significant recognition for his clinical and academic contributions. He received the Top Consenting Physician award for therapeutic studies and holds memberships in leading societies, including ASH, ASCO, SWOG, and the American Society for Blood and Marrow Transplantation. As co-director of the Acute Leukemia Program, he plays a critical role in mentoring trainees, guiding institutional quality initiatives, and shaping leukemia care delivery. Through his dedication to patient-centered treatment, trial innovation, and educational leadership, he is regarded as one of the nation’s top experts in leukemia and hematopoietic cell transplantation.
Education
Medical School:
University of Cape Town Medical School
Residency:
Internal Medicine, Montefiore Hospital
Fellowship:
Hematology/Oncology, City of Hope
Board Certification:
Internal Medicine
Medical Oncology
Awards
- Top Consenting Physician for Therapeutic Studies - Cancer Center Executive Committee
Memberships and affiliations
- Children's Oncology Group
- American Society of Clinical Oncology
- American Society of Hematology
- Southwest Oncology Group
- American Society for Blood and Marrow Transplantation
Research and publications
- WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
- Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
- Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
- Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
- Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
- High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
- Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Other hematologist oncologist listed alphabetically, never by payment.
Browse all doctors →Open trials for these cancers, with the eligibility rules written in plain language.
Search trials →